SOPHiA GENETICS SA SOPH
Set alert
At close · Nov 2
After hours · Nov 2, 6:55 PM ET
- YTD
- +52.25%
- 1 year
- +42.20%
- Open
- 7.66
- Prev close
- 7.63
- Mkt cap
- 605.26M
- Vol
- 405.90K
- Avg vol
- 606.18K
- EPS
- -1.16
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 7.03
- High
- 7.69
- Forward P/E
- -4.09
- Beta
- 1.03
- Short ratio
- 0.89
- Inst. own
- 53.40%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 6, 2024
- 50-d avg
- 3.43
- 200-d avg
- 4.18
- 1y target
- 7.00
News
1 week ago prnewswire.com
SOPHiA GENETICS to Announce Financial Results for Third Quarter 2026 on November 3, 2026
BOSTON and ROLLE, Switzerland, Oct. 20, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for…
-
3 weeks ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Sophia Genetics, Maintains $14 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Sophia Genetics (NASDAQ:SOPH) with a Buy and maintains $14 price target.
-
3 weeks ago benzinga.com
SOPHiA GENETICS, Myriad Genetics Collaborate To Advance New Prostate Cancer-specific Genomic Instability Score Technology
SOPHiA GENETICS (NASDAQ:SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support…
3 weeks ago prnewswire.com
SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
BOSTON, Oct. 8, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic…
3 weeks ago globenewswire.com
Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and SOPHiA GENETICS (NASDAQ: SOPH)…
3 weeks ago defenseworld.net
SOPHiA GENETICS (NASDAQ:SOPH) Insider Manuela Valente Sells 4,240 Shares of Stock
SOPHiA GENETICS SA (NASDAQ: SOPH - Get Free Report) insider Manuela Valente sold 4,240 shares of the stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $8.13,…
3 weeks ago defenseworld.net
SOPHiA GENETICS (NASDAQ:SOPH) CFO George Cardoza Sells 1,592 Shares of Company Stock
SOPHiA GENETICS SA (NASDAQ: SOPH - Get Free Report) CFO George Cardoza sold 1,592 shares of the company's stock in a transaction dated Monday, October 5th. The shares were sold at an average price of…
3 weeks ago defenseworld.net
SOPHiA GENETICS SA (NASDAQ:SOPH) Receives Average Rating of “Hold” from Analysts
Shares of SOPHiA GENETICS SA (NASDAQ: SOPH - Get Free Report) have been assigned a consensus recommendation of "Hold" from the five research firms that are covering the stock, Marketbeat.com reports.…
1 month ago zacks.com
SOPHiA GENETICS (SOPH) Moves 7.0% Higher: Will This Strength Last?
SOPHiA GENETICS (SOPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near…
2 months ago marketbeat.com
When Unusual Volume Isn't Noise: 3 Small-Caps Sending Signals
The volume of shares traded in a session often gets a passing mention in the financial press until a stock experiences unusually high volume. That's because volume can provide an important measure of…
2 months ago defenseworld.net
SOPHiA GENETICS (NASDAQ:SOPH) Sets New 1-Year High – What’s Next?
SOPHiA GENETICS SA (NASDAQ: SOPH - Get Free Report) reached a new 52-week high during trading on Tuesday. The stock traded as high as $8.84 and last traded at $8.45, with a volume of 655541 shares…
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Sophia Genetics, Raises Price Target to $14
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Sophia Genetics (NASDAQ:SOPH) with a Buy and raises the price target from $12 to $14.
-
2 months ago benzinga.com
BTIG Maintains Buy on Sophia Genetics, Raises Price Target to $9
BTIG analyst Mark Massaro maintains Sophia Genetics (NASDAQ:SOPH) with a Buy and raises the price target from $8 to $9.
3 months ago seekingalpha.com
SOPHiA GENETICS SA (SOPH) Q2 2026 Earnings Call Transcript
SOPHiA GENETICS SA (SOPH) Q2 2026 Earnings Call Transcript
3 months ago marketbeat.com
SOPHiA GENETICS Q2 Earnings Call Highlights
SOPHiA GENETICS NASDAQ: SOPH reported second-quarter revenue growth of 27% and raised its full-year revenue outlook, as the precision medicine software company cited accelerating U.S. adoption,…
-
3 months ago benzinga.com
Sophia Genetics Raises FY2026 Sales Guidance from $92.000M-$94.000M to $94.000M-$96.000M vs $93.403M Est
Sophia Genetics (NASDAQ:SOPH) raises FY2026 sales outlook from $92.000 million-$94.000 million to $94.000 million-$96.000 million vs $93.403 million estimate.
-
3 months ago benzinga.com
Sophia Genetics Q2 EPS $(0.30) Misses $(0.20) Estimate, Sales $23.310M Beat $21.729M Estimate
Sophia Genetics (NASDAQ:SOPH) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.20) by 50 percent. This is a 9.09 percent increase over losses of…
3 months ago prnewswire.com
SOPHiA GENETICS Reports Second Quarter 2026 Results
BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the second quarter…
-
3 months ago benzinga.com
SOPHiA GENETICS Announces Global Collaboration To Develop, Validate, And Deploy Two Companion Diagnostics Supporting Precision Oncology Therapies With AstraZeneca
SOPHiA GENETICS (NASDAQ:SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca…
3 months ago prnewswire.com
SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies
BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx)…
3 months ago prnewswire.com
SOPHiA GENETICS to Announce Financial Results for Second Quarter 2026 on August 4, 2026
BOSTON and ROLLE, Switzerland, July 21, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, today announced it will release its financial results for…
3 months ago benzinga.com
This Charles Schwab Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Wall Street analysts change ratings on top stocks. See full changes on analyst ratings page. SCHW, MNST, FDUS have new outlooks.
3 months ago benzinga.com
This Urban Outfitters Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Top Wall Street analysts upgraded URBN, GPN, YETI. See what analysts think of SCHW stock.
3 months ago benzinga.com
This Crane Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Top analysts changed outlook on top names. For all changes, incl. upgrades/downgrades/initiations, see analyst ratings page. Analysts' views on CR stock.
-
3 months ago benzinga.com
HC Wainwright & Co. Initiates Coverage On Sophia Genetics with Buy Rating, Announces Price Target of $12
HC Wainwright & Co. analyst Swayampakula Ramakanth initiates coverage on Sophia Genetics (NASDAQ:SOPH) with a Buy rating and announces Price Target of $12.
4 months ago prnewswire.com
SOPHiA GENETICS Publishes Results of the 2026 Annual General Meeting
Shareholders adopt all proposals, co-founder Dr. Jurgi Camblong elected as Executive Chairman of the Board, Ross Muken elected as new member of the Board ahead of his appointment as CEO effective…
4 months ago prnewswire.com
SOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to Purchase Additional Shares
BOSTON and ROLLE, Switzerland, June 19, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, announced today the closing of its previously announced…
4 months ago seekingalpha.com
SOPHiA Genetics: Strong Growth Meets A Critical Execution Phase
SOPHiA GENETICS is approaching an inflection point in precision medicine, leveraging AI-driven genomic analysis as sequencing costs decline and data complexity rises. SOPH's platform benefits from a…
4 months ago benzinga.com
Stock Market Today: Dow Futures Tumble, S&P 500, Nasdaq Gains As Investors Await FOMC Decision— Amkor, La-Z-Boy In Focus (UPDATED)
(Editor’s note: The future prices of benchmark tracking ETFs and the headline were updated in the story.) U.S. stock futures were mixed on Wednesday, as the Dow Jones fell, while the Nasdaq 100 and…
4 months ago benzinga.com
Sophia Genetics, Ormat Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were mostly higher this morning, with the Nasdaq futures gaining over 100 points on Wednesday.
4 months ago benzinga.com
Sophia Genetics, Ormat Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures mostly higher, Nasdaq futures gain 100+ points. Sophia Genetics (SOPH) falls after pricing public offering of $50M. Other stocks decline in pre-market.
4 months ago benzinga.com
CarMax, Jabil And 3 Stocks To Watch Heading Into Wednesday
U.S. stock futures trading higher. CarMax, Sophia Genetics, Jabil, La-Z-Boy, and Safe Bulkers in focus. La-Z-Boy shares jump 17.7% after earnings.
4 months ago gurufocus.com
SOPHiA GENETICS Announces Pricing of $50 Million Public Offering of Ordinary Shares
SOPHiA GENETICS Announces Pricing of $50 Million Public Offering of Ordinary Shares PR Newswire BOSTON and ROLLE
4 months ago prnewswire.com
SOPHiA GENETICS Announces Pricing of $50 Million Public Offering of Ordinary Shares
BOSTON and ROLLE, Switzerland, June 16, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, announced today the pricing of its previously announced…
-
4 months ago benzinga.com
SOPHiA GENETICS Commences Ordinary Shares Offering; Terms Undisclosed
SOPHiA GENETICS (NASDAQ:SOPH), a global leader in Ai-driven precision medicine, announced today the commencement of a proposed underwritten public offering of its ordinary shares. The Company also…
-
4 months ago benzinga.com
SOPHiA GENETICS Appoints President Ross Muken As CEO, Effective July 1, Succeeding Jurgi Camblong, Who Has Been Nominated As Board Chairman
SOPHiA GENETICS (NASDAQ:SOPH), a global leader in Ai-driven precision medicine, today confirmed, ahead of its 2026 Annual General Meeting (AGM) scheduled for June 18, 2026, the leadership changes…
-
5 months ago benzinga.com
SOPHiA GENETICS Inks MoU With Memorial Sloan Kettering Cancer Center To Form JV Between Two Institutions
SOPHiA GENETICS (NASDAQ: SOPH) today announced that the company has signed a Memorandum of Understanding (MOU) with Memorial Sloan Kettering Cancer Center (MSK) relating to the formation of a joint…
-
6 months ago benzinga.com
Sophia Genetics Affirms FY2026 Sales Guidance of $92.000M-$94.000M vs $93.250M Est
Sophia Genetics (NASDAQ:SOPH) affirms FY2026 sales outlook from $92.000 million-$94.000 million to $92.000 million-$94.000 million vs $93.250 million estimate.
-
6 months ago benzinga.com
Sophia Genetics Q1 EPS $(0.27) Misses $(0.25) Estimate, Sales $21.688M Beat $20.400M Estimate
Sophia Genetics (NASDAQ:SOPH) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.25) by 8 percent. This is a 3.85 percent decrease over losses of…
-
6 months ago benzinga.com
SOPHiA GENETICS Announces Mount Sinai Health System To Implement Its SOPHiA DDM Platform
SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today announced that the Mount Sinai Health System, one of the leading academic health systems in the United States,…
-
6 months ago benzinga.com
BTIG Maintains Buy on Sophia Genetics, Raises Price Target to $8
BTIG analyst Mark Massaro maintains Sophia Genetics (NASDAQ:SOPH) with a Buy and raises the price target from $7 to $8.
8 months ago benzinga.com
Sophia Genetics Q4 Earnings Summary & Key Takeaways
Sophia Genetics Q4 Earnings Summary & Key Takeaways
-
8 months ago benzinga.com
Sophia Genetics Sees FY2026 Sales $92.000M-$94.000M vs $88.000M Est
2026 Financial OutlookBased on information as of today, SOPHiA GENETICS is reaffirming the following guidance:Full-year revenue between $92 million and $94 million, representing approximately 20% to…
-
8 months ago benzinga.com
A Look at Sophia Genetics's Upcoming Earnings Report
A Look at Sophia Genetics's Upcoming Earnings Report
-
8 months ago benzinga.com
SOPHiA GENETICS Adds Two U.S. Healthcare Systems To Its Network To Leverage AI-Native, Cloud-Based SOPHiA DDM To Analyze Complex Genomic Data At Scale
SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today announced the addition of two of the largest U.S. healthcare systems to its network.The two new institutions,…
-
9 months ago benzinga.com
Guggenheim Maintains Buy on Sophia Genetics, Raises Price Target to $7
Guggenheim analyst Subbu Nambi maintains Sophia Genetics (NASDAQ:SOPH) with a Buy and raises the price target from $6 to $7.
-
9 months ago benzinga.com
SOPHiA GENETICS Promotes Ross Muken To CEO, Effective July 2026, As Co‑Founder Jurgi Camblong Moves To Executive Chairman Role
Executive Transition PlanSOPHiA GENETICS today announced the promotion of Ross Muken to Chief Executive Officer, effective July 1, 2026. Mr. Muken, who currently serves as President and has been a…
-
9 months ago benzinga.com
SOPHiA GENETICS Expects FY26 Revenue Of $92M-$94M, up ~20%-22% YoY
Full Year 2026 GuidanceBased on information as of today, SOPHiA GENETICS is providing the following FY 2026 guidance:Full year revenue between $92 million and $94 million, representing approximately…